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Summary We investigated the mechanism of resistance in murine L1210 leukaemia cells selected after
treatment with FCE 23762 methoxymorpholinyl doxorubicin; (MMRDX), a methoxymorpholinyl derivative of
doxorubicin active in vitro and in vivo on multidrug-resistant (mdr) cells, currently undergoing phase I clinical
trials. The resistant subline obtained after repeated in vitro treatments, L1210/MMRDX, is resistant in vitro
and in vivo to all tested methoxymorpholinyl derivatives and to cyanomorpholinyl doxorubicin, but shows
resistance to morpholinyl derivatives only in vivo or following their activation with rat S9 iver fractions in
vitro. LI210/MMRDX cells are sensitive to classic mdr- and altered topoisomerase (AT)-mdr-associated drugs.
These cells do not appear to overexpress the mdrl gene, nor do they exhibit impaired intracellular drug
accumulation and efflux or altered levels of glutathione and glutathione S-transferase. The extent of DNA
single-strand break formation and, after microsomal activation, of DNA interstrand cross-links after treatment
with MMRDX was similar in the parent and the resistant subline. The mechanism of resistance in L1210/
MMRDX cells remains to be identified but may prove a novel one, highly specific for this class of mdr-active
anthracyclines.
Treatment with doxorubicin (DX) or daunorubicin com-
monly selects resistant tumour cells that express the multi-
drug resistant (mdr) phenotype, characterised by enhanced
drug efflux mediated by a high molecular weight membrane
glycoprotein (Endicott & Ling, 1989; Hayes & Wolf, 1990;
Roninson, 1992). Among the several classes of anthracyclines
synthesised in the past 20 years, the morpholinyl anthracyc-
lines are of particular interest since they appear to be active
in vitro and in vivo against mdr tumour cells (Watanabe et
al., 1988; Coley et al., 1990; Ripamonti et al., 1992).
Methoxymorpholinyl doxorubicin (MMRDX) is a
lipophilic compound, able to reach high intracellular levels in
sensitive and mdr tumour cells (Grandi et al., 1990a;
Ripamonti et al., 1992). In addition, compounds of this class
appear to be effective against tumour cells expressing the
altered topoisomerase-mdr phenotype (AT-mdr) (Grandi et
al., 1990b). MMRDX is currently under investigation in
phase I clinical trials. It was thus of interest to determine
whether resistant tumour cells could be selected for resistance
to MMRDX following in vitro exposure to the drug and, if
so, to identify the mechanisms involved. Murine leukaemia
L1210 cells resistant to MMRDX (L1210/MMRDX) were
isolated after repeated in vitro treatments with the drug and
characterised for their pattern of cross-resistance in vitro and
in vivo to a panel of antineoplastic drugs and to selected
anthracyclines bearing either the methoxymorpholinyl or the
morpholinyl substitution on the 3' position of the sugar
moiety.
Materials and methods
Chemicals
3'-Deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (MM-
RDX), 3'-deamino-3'-(4-morpholinyl)doxorubicin (MRDX),
4'-epi-3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin
(4'-epi-MMRDX), 4'-epi-3'-deamino-3'-(4-morpholinyl) dox-
orubicin (4'-epi-MRDX), 4-demethoxy-3'-deamino-3'-(2-
methoxy-4-morpholinyl) doxorubicin (4-dm-MMRDX), 4-
demethoxy-3'-deamino-3'-(2-methoxy-4-morpholinyl) dauno-
rubicin (4-dm-MMRDNR), 4-demethoxy-3'-deamino-3'-(4-
morpholinyl) daunorubicin (4-dm-MRDNR), 3'-deamino-3'-
(3-cyano-4-morpholinyl) doxorubicin (CN-MRDX) (Figure
1) and doxorubicin (DX) were obtained from Farmitalia
Carlo Erba (Milan, Italy).
The following compounds were pharmaceutical prepara-
tions: vinblastine (Eli Lilly, Indianapolis, IN, USA); mel-
phalan (L-PAM), camptothecin and 1-chloro-2,4-dinitro-
benzene (CDNB), glutathione reductase, reduced glutathione
(GSH), NADPH, NADP and 5-5'-dithiobis,2-nitrobenzoic
acid (DTNB) (Sigma, St Louis, MO, USA); mitomycin C
(Kyowa Hakko, Tokyo, Japan); 5-fluorouracil (5-FU)
(Roche, Milan, Italy); 1,3-bis-(2-chloroethyl)-l -nitrosourea
(BCNU) (Nitrumon) (Simes, Vicenza, Italy); cisplatin (Bristol
Myers, Syracuse, NY, USA). DX, MMRDX, MRDX, 4'-epi-
MMRDX, 4'-epi-MRDX, 4-dm-MMRDX, 4-dm-MMRDNR,
4-dm-MRDNR and CN-MRDX were dissolved immediately
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before use and the concentrations were checked spectro-
photometrically.
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Cell cultures
The murine lymphocytic leukaemia cell lines (LI210 and
L1210/MMRDX) were grown in vitro as a stationary suspen-
sion culture in RPMI-1640 medium (Gibco, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum
(Flow, Irvine, UK), 2 mM L-glutamine (Gibco Europe, Glas-
gow, UK) 10I1M P-mercaptoethanol, 100 U ml-' penicillin
and lOO1 g ml-' streptomycin.
Isolation ofL12JO/MMRDX cells
The MMRDX-resistant cell subline (L1210/MMRDX) was
selected in vitro by continuous exposure to 20 ng ml-'
MMRDX, and after 20 passages cloned by limiting dilution
(Norman & Thompson, 1977) in the presence of 20 ng ml-'
MMRDX.
A clone resistant to MMRDX was selected and pro-
pagated in vitro in the absence of the drug. Resistance was
stable for at least 1 year. The doubling time was determined
by seeding the cells at the concentrations of 5 x 104 and 105
cells ml-' (I ml per well, 12-well plates; Costar, Cambridge,
MA, USA). Every 24 h two replicate samples were harvested
and the cell number was determined by a ZBI Coulter
counter (Hialeah, FL, USA).
RNA analysis
Total cellular RNA was extracted by guanidinium
isothiocyanate-caesium chloride centrifugation (Maniatis et
al., 1982).
For Northern blot analysis 20 gig of total RNA was frac-
tionated on 1% agarose gel containing 6.7% formaldehyde
and transferred to nylon membranes (Gene-Screen Plus,
NEN, Boston, MA, USA). The filters were hybridised for
16 h at 42°C in 50% formamide, 10% dextran sulphate, I M
sodium chloride, 1% SDS, 100 gIg ml- 1' of denatured salmon
sperm DNA and 106 c.p.m. ml-' denatured 32P-labelled
probe. After hybridisation, the filters were washed sequen-
tially in 2 x SSC at room temperature and in 2 x SSC, 1%
SDS, at 65°C. The probes utilised were the 1.3-kb EcoRI/
Sall insert of pcDR.3 (Gros et al., 1986) containing the
human mdr gene (Gros et al., 1986) and the 1.8-kb PstI insert
of the murine action gene. Both probes were 32P-labelled
using the multiprime DNA labelling system and [32P]dCTP
(Amersham, Aylesbury, UK).
Glutathione-S-transferase (GST) determination
Expontentially growing cells were lysed by sonication in dis-
tilled water, the cell lysate was centrifuged (10,000 r.p.m. for
15 min) and the supernatant was used for enzyme assay
according to the method of Habig and Jakoby (1981) using
CDNB as substrate.
Glutathione (GSH) determination
Cells were analysed during the exponential phase of growth.
GSH total content was measured as described by Tietze
(1969).
Alkaline elution
DNA damage was detected by the alkaline elution technique
described by Kohn et al. (1981). Briefly, [3H]thymidine-
prelabelled cells were layered and lysed on polycArbonate
filters (0.8 ytm pore size, Nucleopore, Pleasanton, CA, USA)
at room temperature with 5 ml of lysis solution containing
0.1 M glycine, 0.025 M EDTA and 2% SDS (pH 10). After
proteinase K (Merck, Darmstadt, Germany) digestion,
alkaline elution was carried out using a solution containing
0.02M EDTA, 0.1% SDS and tetrapropylammonium hyd-
roxide (Eastman Kodak, Rochester, NY, USA) to give a pH
of 12.2. The pumping rate was 0.04 ml min-' and fractions
were collected at 180 min intervals for 15 h. 3H-labelled DNA
was quantitated by liquid scintillation P counter.
In experiments carried out to identify DNA damage after
microsomal activation of MMRDX, cells were incubated
with the drug in the presence of the S9 fraction of rat liver
(1 mg of protein per ml), glucose 6-phosphate 1 mg ml-' and
NADP 2 mg ml-' in a final volume of 1 ml for 1 h before
being processed as for DNA single-stand break assay.
Intracellular drug accumulation and retention
Intracellular drug content was determined in L1210 and
L1210/MMRDX cells treated with 10 and 100 nM MMRDX
and incubated at 37°C for up to 4 h.
For drug efflux determination, cells incubated with
MMRDX for 1 h were washed in PBS, then resuspended in
drug-free medium and reincubated at 37°C.
Drug was extracted from the cells with 0.6 M hydrochloric
acid-ethanol (1:1 mixture) and samples were analysed in an
HPLC system using a C18 reversed-phase column and a
spectrofluorimeter as detector (excitation and emission
wavelengths were 479 and 593 nm respectively).
The intracellular accumulation of the drug at various time
intervals is reported as ng per 106 cells.
In vitro drug sensitivity
Exponentially growing L1210 and L1210/MMRDX cells
were exposed to various concentrations of drugs continuously
for 48 h. The antiproliferative activity of the drugs was
evaluated by counting surviving cells with a Coulter counter
and results were expressed as IC50 (dose causing 50% inhibi-
tion of cell growth in treated cultures relative to untreated
controls).
The cytotoxicity of morpholinyl derivatives on L1210 and
L1210/MMRDX cells with and without microsomal activa-
tion was determined on cells incubated at 37°C in aerobic
conditions for 1 h in the presence of various concentrations
of drugs with or without an incubation mixture consisting of
0.33 mg ml-' protein of S9 fraction of rat liver homogenate,
0.33 mg ml-' NADP and 0.16mg ml-' glucose 6-phosphate
(Boehringer Mannheim Italia, Milan, Italy).
S9 was prepared according to the method of Hilton and
Sartorelli (1970). The incubation was stopped by washing
cells with ice-cold RPMI-1640 medium. The cells were then
incubated for 48 h in drug-free medium and cell growth was
assessed as described above.
In vivo studies
Inbred DBA2 and CD2F1 adult female mice (Charles River,
Calco, Italy), 2-3 months old, weighing 20-24 g, were kept
under standard laboratory conditions.
The L1210, obtained from the National Cancer Institute
(NIH, Bethesda, MD, USA), and L1210/MMRDX mouse
leukaemias were maintained by weekly i.p. passages of 106
cells in DBA2 mice; in the case of the L1210/MMRDX
subline mice were treated weekly with 0.05 mg kg-'
MMRDX i.p. For experimental studies i.p. inocula of 105
cells into CD2F1 mice were used. Drugs were administered
i.p. on day 1, control animals receiving vehicle alone. Drug
activity was determined by comparing the median survivalRESISTANCE TO METHOXYMORPHOLINYL DX, FCE 23762 317
time (MST) of the treated group with that of the control
group and results are expressed as %T/C where:
%T/C
MST of treated group
MST of control group
x 100
Toxicity was evaluated on tumour-bearing mice on the basis
of the gross autopsy findings and weight loss.
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L1210/MMRDX cells are 8.5-fold resistant in vitro to the
selecting agent (Table I), and maintain resistance after > 100
passages in drug-free medium. L1210/MMRDX cells have
the same doubling time (9 h) and in vivo tumorigenicity
(8-10 days) as the parent line.
The levels of GSH (7.76 and 7.83 fmol per cell) and of
glutathione S-transferase (100 ± 14 and 111 ± 8 relative
units) are also similar in L1210 and L1210/MMRDX cells.
Results obtained comparing the levels of mdr-J mRNA in
L1210, L1210/MMRDX and L1210/DX cells a subline 20-
fold resistant to DX (not shown) as the positive control
clearly indicate that L1210/MMRDX cells do not over-
express mdr-J mRNA gene.
Intracellular accumulation and efflux
The kinetics of accumulation and efflux in L1210 and L1210/
MMRDX cells exposed to 10 and 100 nM MMRDX is pres-
ented in Figure 2a and b. At all time points the intracellular
levels of MMRDX are similar in both cell lines.
Alkaline elution studies
The frequency of single-strand breaks (DNA-SSBs) and for-
mation of DNA interstrand cross-links (DNA-ISCs) in res-
ponse to MMRDX treatment is reported in Table II. No
differences were observed between L1210 and L1210/
MMRDX cells. DNA-SSB levels after exposure to 1 ltg ml-'
were similar to those found with DX at the same concentra-
tion (not shown). The repair of DNA-SSBs appeared very
quick as no breaks were detectable after 1 h drug washout in
both L1210 and L1210/MMRDX cells.
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Figure 2 Time response of MMRDX accumulation ( ) and
efflux ... .). a, L1210 cells; b, L1210/MMRDX cells treated with
10 nm (filled symbols) and 100 nm (open symbols) MMRDX.
Values represent the average of six determinations. Bars = s.e.;
when bars are not shown they are smaller than the symbol.
Table I In vitro and in vivo activity of different antineoplastic agents against L1210 and L1210/MMRDX
leukaemias
In vivo anti-tumour activity
In vitroa Dose L121OC L1210/MMRDX
Compound RIb (mgkg-) %T/Cd TOP %T/Cd TOXY
MMRDX 8.5 0.11 138 0/10 96 0/40
0.13 163 0/10 100 10/20
DX 0.9 10 - - 208 0/20
13 200 0/10 229 3/20
Vinblastine 1.2 3 156 0/10 163 0/10
5.9 63 9/10 63 8/10
Camptothecin 1.3 20 194 0/10 225 0/10
30 88 7/10 75 10/10
L-PAM 0.7 10 169 0/30 289 0/10
15 211 1/30 >667 1/10
Cisplatin 0.5 7.7 175 0/10 311 0/10
10 100 7/10 >667 1/10
BCNU 0.7 30 394 0/10 367 0/10
5-FU 0.5 200 175 0/10 172 0/10
300 188 0/10 178 2/10
Mitomycin C 0.3 5 125 0/10 >750 0/10
9 156 0/10 719 0/10
aDrug sensitivity was determined by counting surviving cells after 48 h of continuous exposure to at least
four concentrations of each drug. bResistance index: ratio between IC5o values on resistant cells and sensitive
cells. CCD2F1 mice were given an injection of 105 cells i.p. and treated i.p. on day 1. dMedian survival time of
treated mice/median survival time of controls x 100. eNumber of toxic deaths/number of mice.
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MMRDX did not cause DNA-ISCs in either cell line when
incubated without rat liver S9 fraction; conversely, after I h
incubation in the presence of rat liver S9 fraction the number
of DNA-ISCs appeared similar in L1210 and L1210/
MMRDX cells (Table II). In L1210 cells 30% and 55% of
DNA-ISCs were repaired after 1 and 4 h respectively; in
L1210/MMRDX 20% and 64%.
In both cell lines DNA-ISCs were no longer detectable at
24 h. These data suggest that the mechanism of resistance is
not related to differences in DNA damage produced by
MMRDX.
Pattern ofin vitro and in vivo sensitivity to different
anti-tumour compounds
The activity of different anti-tumour molecules tested in vitro
and in vivo on L1210/MMRDX cells in comparison with
L1210 cells is reported in Table I. The subline is resistant to
MMRDX and sensitive to all other tested drugs, including
Table II DNA-SSBs and DNA-ISCs in rad equivalents induced by
MMRDX treatment
DNA Dose Cell line
damage (gml-') L1210 L1210/MMRDX
DNA-SSBSa 1 111.4 36 105.6± 16
1 220.6 76 208.8 45
DNA-ISCsb 0.5c 70 7 91 ± 7
1 169.6±30 170.7±39
aCells were treated with MMRDX for 1 h. Each value is the
mean ± s.e. of five experiments. bCells were treated with MMRDX
for 1 h in the presence of S9 fraction of rat liver homogenate. Each
value is the mean ± s.e. of at least three experiments. cResults from
one experiment ± s.e. of three replicate samples.
mdr-inactive drugs such as DX and vinblastine. Moreover,
the anti-tumour activity of L-PAM, cisplatin and mitomycin
C is markedly higher in the resistant than in the parent line.
Pattern ofin vitro and in vivo sensitivity to morpholinyl
anthracyclines
It is reported that most morpholinylanthracyclines are
activated to highly cytotoxic metabolites when administered
in vivo and in vitro in the presence of liver microsomes (Lau
et al., 1989; 1991; Duran et al., 1991; Lewis et al., 1992). The
relative sensitivity of L1210/MMRDX cells to a series of
molecules of the same chemical class (Figure 1) was thus
assayed with and without rat liver homogenate (S9) (Table
III). L1210/MMRDX cells are resistant to all tested meth-
oxymorpholinyl anthracyclines with resistance indexes (RI)
ranging between 10.5 and 4.2. The RI values are unaltered
after treatment with S9. Conversely, L1210/MMRDX cells
are sensitive to the analogues bearing the morpholinyl in-
stead of the methoxymorpholinyl group but become resistant
after treatment with S9. In particular, the cytotoxicity of
MRDX and 4'-epi-MRDX is increased 50-fold after micro-
somal activation.
The only cyanomorpholinyl derivative tested, CN-MRDX,
was inactive, independently of the treatment with mic-
rosomes, which also did not augment its cytotoxic activity.
Results reported in Table IV indicate that, when
administered in vivo to mice bearing ascitic L1210 and
L1210/MMRDX cells, all tested compounds have anti-
tumour activity against the sensitive line, and are inactive
against the resistant one. These results confirm the data
obtained in vitro, which indicate that L1210/MMRDX cells
are resistant to methoxymorpholinyl derivatives, but only
show resistance to morpholinyl derivatives after activation in
the presence of liver microsomes.
Table III Cytotoxic activity of different morpholinyl derivatives against L1210 and L1210/MMRDX cells with and without rat
liver microsomes (S9)
IC50 (ngml-') - S9a IC50 (ngml-') + S9'
Compound L1210 L1210/MMRDX Rib L1210 L1210/MMRDX Rib
MMRDX 9.8 ± 3 103.6 ± 20 10.5 3.5 ± 0.7 26.5 ± 4 7.5
4'-epi-MMRDX 11.7 ±2 49.7 ± 11 4.2 2 ±0.5 6.8±2 3.4
4-dm-MMRDNR 13.5 ± 0.6 108.8 ± 8 8 12.2 ± 0.8 83.2 ± 5 6.8
4-dm-MMRDX 10.2 ±2.4 93 ± 20 9.1 2.2 ±0.5 11.6 2 5.2
MRDX 60 ± 11 83.4 ± 16 1.3 1.1 ±0.3 14.7±4 13.3
4'-epi-MRDX 130 ± 19 122.2 ± 24 0.9 2.8 ± 0.5 29.4 8 10.5
4-dm-MRDNR 94.8 ± 5 181 ± 12 1.9 17.1 ± 3 67.1 ± 27 3.9
CN-MRDX 0.25 ±0.08 7.7 ± 0.2 30.8 0.26 ±0.06 7.9 0.5 30.3
'50% inhibitory concentration (IC50) represents the mean ± s.e. from dose response curves ofat least three experiments. Cells
were treated with the drug for I h in the presence ( + S9) and in the absence ( - S9) of rat liver homogenate; S9 fraction.
bResistance index: ratio between IC50 values on resistant cells and sensitive cells.
Table IV Anti-tumour activity of different morpholinyl derivatives against
ascitic L1210 and L1210/MMRDX leukaemias
Dose L121Oa LJ2JO/MMRDXG
Compound (mgkg-') %T/C TOXr %T/Cb TOXC
MMRDX 0.11 138 0/10 96 0/40
0.13 163 0/10 100 10/20
4-dm-MMRDNR 0.24 150 0/10 100 0/10
0.36 175 0/10 106 7/10
MRDX 0.075 150 0/10 100 0/10
0.11 150 7/10 113 9/10
4'-epi-MMRDX 0.3 156 0/10 100 0/10
0.45 125 9/10 100 1/10
4-dm-MRDNR 0.51 188 0/10 129 0/10
0.66 206 1/10 104 7/10
CN-MRDX 0.0063 150 0/10 113 0/10
0.0125 178 2/10 113 0/10
'CD2Fl mice were given an injection of 10' leukaemia cells i.p. and were
treated i.p. on day 1. bMedian survival time of treated mice/median survival
time of controls x 100. CNumber of toxic deaths/number of mice.RESISTANCE TO METHOXYMORPHOLINYL DX, FCE 23762 319
Discussion
We describe the isolation and characterisation of a murine
L1210 cell line selected for resistance to MMRDX, a new
anthracycline derivative undergoing phase 1 clinical studies.
The mode of action of MMRDX appears to differ from that
of anthracyclines (Ripamonti et al., 1992), since it is active
against mdr and AT-mdr cells (Grandi et al., 1990b), and
forms DNA-ISCs when tested in the presence of liver micro-
somes (Duran et al., 1991; Lau et al., 1991).
Our results using L1210 cells indicate that exposure to
MMRDX selects a stable cell population specifically resistant
in vitro and in vivo to the selecting agent and compounds of
the same chemical class, the morpholinyl anthracyclines.
L1210/MMRDX cells were found to be sensitive to anti-
tumour drugs associated with the classic mdr phenotype and
to topoisomerase II inhibitors. No overexpression of the
mdrl gene, or any alteration in drug accumulation or efflux
was identified in these resistant cells. The levels of GSH and
GST were found to be unchanged in L1210/MMRDX cells,
suggesting that GSH-mediated detoxification is not the basis
of resistance to this compound.
As regards the DNA damage induced by MMRDX treat-
ment, we found that the number of DNA-SSBs and, after
microsomal activation, of DNA-ISCs was similar in L1210
and L1210/MMRDX cells.
Although these data suggest that the mechanism of resist-
ance selected by treatment with MMRDX is not related to
differences in DNA damage or in repair mechanisms, the
drug concentrations required to obtain a number of DNA
lesions detectable by alkaline elution are far greater than the
minimal cytotoxic concentrations. Therefore, we cannot ex-
clude the possibility that the different drug sensitivity is due
to a more efficient repair of a lower number of DNA lesions.
The pattern of cross-resistance to morpholinylanthracyc-
lines is an interesting finding: in fact, all compounds bearing
the methoxymorpholinyl group are inactive in vitro and in
vivo against L1210/MMRDX cells, as well as cyanomor-
pholinyl doxorubicin, whereas the morpholinyl derivatives
are inactive only in vivo, and in vitro when tested in the
presence of rat liver S9 fraction. Such results can be inter-
preted assuming that: (a) the active metabolite(s) of
MMRDX and MRDX have similar modes of action and
mechanisms of resistance; (b) the mechanism of resistance to
MMRDX and its active metabolite is the same, as demon-
strated by the evidence that the RIs before and after
metabolic activation of MMRDX are equivalent; (c) CN-
MRDX is inactive against L1210/MMRDX cells without
requiring metabolic activation. Therefore is seems plausible
that MMRDX, as well as its active metabolite(s), MRDX
active metabolite(s) and CN-MRDX act by the same
mechanism.
CN-MRDX is known to alkylate DNA very efficiently,
causing many DNA adducts and DNA-ISCs (Westendorf et
al., 1985; Jesson et al., 1989).
The anti-tumour activity of alkylating agents such as L-
PAM, BCNU, cisplatin and mitomycin C against L1210/
MMRDX cells suggests that, if MMRDX activity is
associated with alkylating species, its mechanism of interac-
tion with macromolecules is different from that of the clas-
sical alkylating agents.
In conclusion, L1210/MMRDX is a cell line which may be
a useful tool for investigating the mechanism of in vitro and
in vivo resistance to MMRDX and its analogues.
The results obtained so far strongly support the view that
this drug is profoundly different from previously investigated
anthracyclines and should not be considered as one of the
various DX analogues, but as a new type of anti-tumour
drug.
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